

*This guideline may contain custom content that has been modified from the MCG care guidelines and has not been reviewed or approved by MCG Health.*

## SHP Apixaban (Eliquis) Drug Level

AUTH: SHP Medical 303 v2 (AC)

**MCG Health**  
Ambulatory Care  
24th Edition

[Link to Codes](#)

- [Coverage](#)
- [Application to Products](#)
- [Authorization Requirements](#)
- [Description of Item or Service](#)
- [Exceptions and Limitations](#)
- [Clinical Indications for Procedure](#)
- [Document History](#)
- [Coding Information](#)
- [References](#)
- [Codes](#)

---

### Coverage

[Return to top of SHP Apixaban \(Eliquis\) Drug Level - AC](#)

See the appropriate benefit document for specific coverage determination. Member specific benefits take precedence over medical policy.

---

### Application to Products

[Return to top of SHP Apixaban \(Eliquis\) Drug Level - AC](#)

Policy is applicable to all products.

---

### Authorization Requirements

[Return to top of SHP Apixaban \(Eliquis\) Drug Level - AC](#)

Pre-certification by the Plan is required.

---

### Description of Item or Service

[Return to top of SHP Apixaban \(Eliquis\) Drug Level - AC](#)

Apixaban Drug Level testing the level of a direct oral anticoagulant (DOAC) medication in the blood stream.

---

### Exceptions and Limitations

[Return to top of SHP Apixaban \(Eliquis\) Drug Level - AC](#)

There is insufficient scientific evidence to support the medical necessity of this service as it is not shown to improve health outcomes upon technology review.

---

### Clinical Indications for Procedure

[Return to top of SHP Apixaban \(Eliquis\) Drug Level - AC](#)

- NA

---

### Document History

[Return to top of SHP Apixaban \(Eliquis\) Drug Level - AC](#)

- Revised Dates:
- Reviewed Dates:
  - 2021: August
  - 2020: August
- Effective Date: April 2019

---

### Coding Information

[Return to top of SHP Apixaban \(Eliquis\) Drug Level - AC](#)

- CPT/HCPCS codes covered if policy criteria is met:
  - None
- CPT/HCPCS codes considered not medically necessary per this Policy:

◦ CPT 80299 - Quantitation of therapeutic drug, not elsewhere specified

## References

[Return to top of SHP Apixaban \(Eliquis\) Drug Level - AC](#)

References used include but are not limited to the following:

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; Uptodate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2021). Retrieved Aug 03, 2021, from Hayes: <https://evidence.hayesinc.com/search?q=%257B%2522text%2522:%2522apixaban%2520level%2522,%2522title%2522:null,%2522termsource%2522:%2522searchbar%2522,%2522page%2522:%257B%2522page%2522:0,%2522size%2522:50%257D,%2522type%2522:%2522all%2522,%2522sources%2522>

(2021). Retrieved Aug 03, 2021, from Centers for Medicare and Medicaid Services: <https://www.cms.gov/medicare-coverage-database/new-search/search-results.aspx?keyword=Apixaban&keywordType=starts&areald=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all>

(2021). Retrieved Aug 03, 2021, from AIM Specialty Health: <https://aimspecialtyhealth.com/resources/clinical-guidelines/genetic-testing/>

(2021). Retrieved Aug 03, 2021, from National Comprehensive Cancer Network: <https://www.nccn.org/guidelines/submissions-licensing-and-permissions/submission-request-history>

(2021, Jun 07). Retrieved Aug 03, 2021, from MCG: <https://careweb.careguidelines.com/ed24/index.html>

Apixaban. (2021, Jul 27). Retrieved Aug 02, 2021, from DynaMed: <https://www.dynamed.com/drug-monograph/apixaban-12#GUID-20862582-F5F2-45A5-9C6C-52F9157F7022>

Leung, L. (2021, Jul 25). Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects. Retrieved Aug 03, 2021, from UpToDate: [https://www.uptodate.com/contents/direct-oral-anticoagulants-doacs-and-parenteral-direct-acting-anticoagulants-dosing-and-adverse-effects?sectionName=DIRECT%20FACTOR%20Xa%20INHIBITORS&search=factor%20xa%20level&topicRef=1368&anchor=H15&source=see\\_link#H15](https://www.uptodate.com/contents/direct-oral-anticoagulants-doacs-and-parenteral-direct-acting-anticoagulants-dosing-and-adverse-effects?sectionName=DIRECT%20FACTOR%20Xa%20INHIBITORS&search=factor%20xa%20level&topicRef=1368&anchor=H15&source=see_link#H15)

Apixaban (Eliquis) for Treatment of Acute Venous Thromboembolism (VTE) and VTE Secondary Prevention - ARCHIVED Sep 15, 2014. (2020). Retrieved Aug 4, 2020, from Hayes: <https://evidence.hayesinc.com/report/pg.282>

Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects. (2020, July 17). Retrieved August 4, 2020, from UpToDate 2: [https://www.uptodate.com/contents/direct-oral-anticoagulants-doacs-and-parenteral-direct-acting-anticoagulants-dosing-and-adverse-effects?search=chromogenic%20anti-factor%20assay&topicRef=1368&source=see\\_link#H15](https://www.uptodate.com/contents/direct-oral-anticoagulants-doacs-and-parenteral-direct-acting-anticoagulants-dosing-and-adverse-effects?search=chromogenic%20anti-factor%20assay&topicRef=1368&source=see_link#H15)

Douxflis, J., Ageno, W., Samama, C., Lessire, S., Ten Cate, H., Verhamme, P., . . . Mullier, F. (2018, Feb). Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. Retrieved Feb Mar, 2019, from PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/29193737>

ELIQUIS. (2016). Retrieved Aug 4, 2020, from FDA 2: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2019/202155s021bl.pdf#page=41](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202155s021bl.pdf#page=41)

Evidence-Based Clinical Practice Guidelines: Antithrombotic Therapy for VTE Disease. (2016, Feb 1). Retrieved Aug 4, 2020, from American College of Chest Physicians (CHEST): [https://journal.chestnet.org/article/S0012-3692\(15\)00335-9/fulltext](https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext)

FDA approves first generics of Eliquis. (2019, Dec 23). Retrieved Aug 4, 2020, from FDA: <https://www.fda.gov/news-events/press-announcements/fda-approves-first-generics-eliquis>

Ikeda, K., & Tachibana, H. (2016, Feb). Clinical implication of monitoring rivaioxaban and apixaban by using anti-factor Xa assay in patients with non-valvar atrial fibrillation. Retrieved Mar 14, 2019, from PubMed: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4759124/>

Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. (2018). Retrieved Aug 4, 2020, from Journal of Thrombosis and Haemostasis: [https://limo.libis.be/primo-explore/fulldisplay?docid=LIRIAS1555251&context=L&vid=Lirias&search\\_scope=Lirias&tab=default\\_tab&lang=en\\_US&fromSitemap=1](https://limo.libis.be/primo-explore/fulldisplay?docid=LIRIAS1555251&context=L&vid=Lirias&search_scope=Lirias&tab=default_tab&lang=en_US&fromSitemap=1)

Overanticoagulation management. (2018, Dec 04). Retrieved Mar 13, 2019, from DynaMed Plus: <http://www.dynamed.com/topics/dmp~AN~T114834>

Periprocedural management of patients on long-term anticoagulation. (2018, Oct). Retrieved Mar 14, 2019, from DynaMed: <http://www.dynamed.com/topics/dmp~AN~T227537/Periprocedural-management-of-patients-on-long-term-anticoagulation#Factor-Xa-inhibitors>

Thromboembolic Prophylaxis in Atrial Fibrillation. (2020). Retrieved Aug 4, 2020, from Dynamed:  
<https://www.dynamed.com/management/thromboembolic-prophylaxis-in-atrial-fibrillation>

---

## Codes

[Return to top of SHP Apixaban \(Eliquis\) Drug Level - AC](#)

**CPT® : 80299**

*CPT copyright 2020 American Medical Association. All rights reserved.*

---

MCG Health  
*Ambulatory Care 24th Edition*